President Donald Trump announced a new executive order aimed at cutting medication costs. The move signals a renewed push on a long-standing issue. On Monday, Trump pledged to sign a new directive that could significantly affect how Medicare pays for certain drugs.
The central idea is to introduce a Fair Drug Pricing Policy. Under this policy, Medicare payments would match the lowest price paid by other wealthy nations. Trump said this would end the era of Americans overpaying for medications. He promised action during a post on his social media platform Sunday evening.
Trump wrote, “I will be instituting a MOST FAVORED NATION’S POLICY.” He explained that the U.S. would no longer pay more than countries with better-negotiated prices. By Monday morning, he confirmed he would sign the order from the White House.
This plan targets medications given in doctors’ offices, such as cancer treatments and other injectable drugs. These are drugs covered under Medicare Part B. That program serves millions of older Americans. Trump believes that linking prices to those paid by other developed nations will save taxpayers billions.
He emphasized that this Fair Drug Pricing Policy would bring fairness back to the healthcare system. Trump also took another swing at pharmaceutical companies. He accused them of blaming high prices on research costs. He claimed Americans alone have carried those burdens for too long.
Previously, Trump attempted a similar move during his presidency. However, courts blocked it before it could take effect. The pharmaceutical industry strongly opposed it. They argued it would harm innovation and reduce profits.
Still, Trump remains defiant. He pointed out that campaign donations from drug companies won’t sway him or the Republican party.
Critics note that the policy might not apply to everyday pharmacy prescriptions. Only those administered in clinical settings fall under this plan.
Regardless, the proposed Fair Drug Pricing Policy has once again stirred debate. It raises questions about healthcare fairness, drug industry power, and patient protection. As the 2024 election buzz grows louder, Trump’s healthcare proposals are likely to gain more attentio.
For more political updates, visit DC Brief.
